Home

WorldCat Home About WorldCat Help

Search

Search for Library Items Search for Lists Search for Contacts Search for a Library

Create lists, bibliographies and reviews: or

Cite/Export

Cite/Export

Copy a citation

APA (6th ed.)

Chicago (Author-Date, 15th ed.)

Harvard (18th ed.)

MLA (7th ed.)

Turabian (6th ed.)

Export a citation
Export to RefWorks Export to EndNote / Reference Manager Export to EasyBib
Export to EndNote / Reference Manager(non-Latin) Cancel
Note: Citations are based on reference standards. However, formatting rules can vary widely between applications and fields of interest or study. The specific requirements or preferences of your reviewing publisher, classroom teacher, institution or organization should be applied.
Print
E-mail

E-mail

All fields are required.

The E-mail Address(es) field is required. Please enter recipient e-mail address(es).

The E-mail Address(es) you entered is(are) not in a valid format. Please re-enter recipient e-mail address(es).

You may send this item to up to five recipients.
Enter recipient e-mail address(es): Separate up to five addresses with commas (,)
The name field is required. Please enter your name.
Enter your name: Subject:
The E-mail message field is required. Please enter the message.
E-mail Message: I thought you might be interested in this item at http://www.worldcat.org/oclc/1090385001 Title: CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Publisher: Ottawa (ON) : CADTH, February 21, 2018. OCLC:1090385001

Please verify that you are not a robot.

Cancel
Share
Permalink

Permalink

Copy this URL to link to this page:

Write a review
Rate this item:
- 1
- 2
- 3
- 4
- 5

CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Preview this item

Checking...

CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Author:	CADTH Canadian Drug Expert Committee,; Canadian Agency for Drugs and Technologies in Health,
Publisher:	Ottawa (ON) : CADTH, February 21, 2018.
Series:	Common drug review clinical review report.
Edition/Format:	eBook : Document : English : Version 1.0
Summary:	The CADTH Canadian Drug Expert Committee (CDEC) recommends that guselkumab be reimbursed for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, with the following criteria and condition. Reimburse in a manner similar to other biologics for the treatment of moderate-to-severe plaque psoriasis. Treatment should be discontinued if a response to treatment Read more...
Rating:	(not yet rated) 0 with reviews - Be the first.
Subjects	Psoriasis -- drug therapy. Antibodies, Monoclonal -- therapeutic use. Antibodies, Monoclonal -- economics. View all subjects
More like this	User lists Similar Items

Find a copy online

Links to this item

ncbi.nlm.nih.gov

Find a copy in the library

Finding libraries that hold this item...

Details

Material Type:	Document, Internet resource
Document Type:	Internet Resource, Computer File
All Authors / Contributors:	CADTH Canadian Drug Expert Committee,; Canadian Agency for Drugs and Technologies in Health,
OCLC Number:	1090385001
Notes:	"Final."
Description:	1 online resource (1 PDF file (9 pages)).
Series Title:	Common drug review clinical review report.
Other Titles:	Guselkumab (Tremfya -- janssen inc.)

Abstract:

The CADTH Canadian Drug Expert Committee (CDEC) recommends that guselkumab be reimbursed for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, with the following criteria and condition. Reimburse in a manner similar to other biologics for the treatment of moderate-to-severe plaque psoriasis. Treatment should be discontinued if a response to treatment with guselkumab has not been demonstrated after 16 weeks.

Reviews

User-contributed reviews

Linked Data

Primary Entity

Related Entities

<http://experiment.worldcat.org/entity/work/data/8985178467#Organization/cadth_canadian_drug_expert_committee> # CADTH Canadian Drug Expert Committee,
    a schema:Organization ;
    schema:name "CADTH Canadian Drug Expert Committee," ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Place/canada> # Canada.
    a schema:Place ;
    schema:name "Canada." ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Series/cadth_common_drug_review> # CADTH common drug review
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1090385001> ; # CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
    schema:name "CADTH common drug review" ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1090385001> ; # CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
    schema:name "Common drug review clinical review report." ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Topic/antibodies_monoclonal_economics> # Antibodies, Monoclonal--economics
    a schema:Intangible ;
    schema:name "Antibodies, Monoclonal--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Topic/antibodies_monoclonal_therapeutic_use> # Antibodies, Monoclonal--therapeutic use
    a schema:Intangible ;
    schema:name "Antibodies, Monoclonal--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Topic/drug_costs> # Drug Costs
    a schema:Intangible ;
    schema:name "Drug Costs"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Topic/insurance_health_reimbursement> # Insurance, Health, Reimbursement
    a schema:Intangible ;
    schema:name "Insurance, Health, Reimbursement"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Topic/interleukin_23_subunit_p19_economics> # Interleukin-23 Subunit p19--economics
    a schema:Intangible ;
    schema:name "Interleukin-23 Subunit p19--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Topic/interleukin_23_subunit_p19_therapeutic_use> # Interleukin-23 Subunit p19--therapeutic use
    a schema:Intangible ;
    schema:name "Interleukin-23 Subunit p19--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985178467#Topic/psoriasis_drug_therapy> # Psoriasis--drug therapy
    a schema:Intangible ;
    schema:name "Psoriasis--drug therapy"@en ;
    .

<http://id.loc.gov/vocabulary/countries/onc>
    a schema:Place ;
    dcterms:identifier "onc" ;
    .

<http://www.worldcat.org/title/-/oclc/1090385001>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/1090385001> ; # CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
    schema:dateModified "2019-12-06" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .

Content-negotiable representations

Turtle (text/turtle)
JSON-LD (application/ld+json)
RDF/XML (application/rdf+xml)
N-TRIPLES (text/plain)
HTML+RDFa (text/html)

Please sign in to WorldCat

Don't have an account? You can easily create a free account.

You:	Sign In \| Register \| My WorldCat \| My Lists \| My Watchlist \| My Reviews \| My Tags \| My Saved Searches
WorldCat:	Home \| About \| Help \| Search